{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:48:11Z","timestamp":1792784891299,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TH 2172\/2-2"],"award-info":[{"award-number":["TH 2172\/2-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["2270\/1-1"],"award-info":[{"award-number":["2270\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Brigitte and Dr. Konstanze Wegener Foundation","id":[{"id":"https:\/\/ror.org\/00bgszw56","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Head and neck cancer (HNC) is highly immunosuppressive. Despite advances with immune checkpoint (IC) inhibitors, many HNC patients fail to respond. Tumour-derived small extracellular vesicles (sEVs) may contribute to immune evasion and therapy resistance, possibly by altering T-cell phenotypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Plasma sEVs were isolated from HNC patient samples and controls via size-exclusion chromatography. The plasma sEVs were characterised and analysed for their effects on CD4\u207a and CD8\u207a T-cell function, IC levels and gene expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      HNC patient-derived sEVs inhibit CD4\n                      <jats:sup>+<\/jats:sup>\n                      and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell function and promote CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell apoptosis, correlating with disease progression. Plasma sEVs can enhance the conversion of ATP to AMP and modulate the expression of ectonucleotidases. IC profiling revealed complex alterations, with CD4\u207a T cells showing increased TIGIT and CTLA-4 but decreased BTLA, PD-1, and LAG-3 expression, whereas CD8\u207a T cells showed a downregulation of both inhibitory and stimulatory ICs. PD-1 blockade did not completely prevent sEV-mediated T-cell suppression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings suggest that plasma sEVs contribute to systemic immune modulation in HNC by inducing dysfunctional T-cell phenotypes. The ability of plasma-derived sEVs to modulate IC expression on T cells underscores the need for further investigation into their relevance for immunotherapeutic strategies in HNC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-026-03606-8","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T08:32:32Z","timestamp":1790411552000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Small extracellular vesicles from the plasma of head and neck cancer patients induce dysfunctional T cell phenotypes"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3388-698X","authenticated-orcid":false,"given":"Luisa","family":"Tengler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin K.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Bieback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"R\u00f6th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Mellein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5491-1593","authenticated-orcid":false,"given":"Marie-Nicole","family":"Theodoraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Sch\u00fctz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Scherl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Rotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Affolter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"key":"3606_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3606_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1158\/1078-0432.CCR-17-1261","volume":"24","author":"TL Whiteside","year":"2018","unstructured":"Whiteside TL. Head and neck carcinoma immunotherapy: facts and hopes. Clin Cancer Res. 2018;24:6\u201313.","journal-title":"Clin Cancer Res"},{"key":"3606_CR3","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr., Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856\u201367.","journal-title":"N Engl J Med"},{"key":"3606_CR4","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, de Castro G Jr, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915\u201328.","journal-title":"Lancet"},{"key":"3606_CR5","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1200\/JCO.22.00332","volume":"41","author":"RI Haddad","year":"2023","unstructured":"Haddad RI, Harrington K, Tahara M, Ferris RL, Gillison M, Fayette J, et al. Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent\/metastatic squamous cell carcinoma of the head and neck: The final results of CheckMate 651. J Clin Oncol. 2023;41:2166\u201380.","journal-title":"J Clin Oncol"},{"key":"3606_CR6","doi-asserted-by":"publisher","first-page":"4843","DOI":"10.1158\/1078-0432.CCR-16-2819","volume":"23","author":"S Ludwig","year":"2017","unstructured":"Ludwig S, Floros T, Theodoraki MN, Hong CS, Jackson EK, Lang S, et al. Suppression of lymphocyte functions by plasma exosomes correlates with disease activity in patients with head and neck cancer. Clin Cancer Res. 2017;23:4843\u201354.","journal-title":"Clin Cancer Res"},{"key":"3606_CR7","doi-asserted-by":"publisher","unstructured":"Coray M, Goldi V, Schmid L, Benecke L, Figueiro F, Muller L. Differential immunomodulatory effects of head and neck cancer-derived exosomes on B cells in the presence of ATP. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms232214446.","DOI":"10.3390\/ijms232214446"},{"key":"3606_CR8","doi-asserted-by":"publisher","first-page":"7249","DOI":"10.4049\/jimmunol.180.11.7249","volume":"180","author":"A Clayton","year":"2008","unstructured":"Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z. Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol. 2008;180:7249\u201358.","journal-title":"J Immunol"},{"key":"3606_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.canlet.2020.02.037","volume":"478","author":"F Tong","year":"2020","unstructured":"Tong F, Mao X, Zhang S, Xie H, Yan B, Wang B, et al. HPV + HNSCC-derived exosomal miR-9 induces macrophage M1 polarization and increases tumor radiosensitivity. Cancer Lett. 2020;478:34\u201344.","journal-title":"Cancer Lett"},{"key":"3606_CR10","doi-asserted-by":"publisher","unstructured":"Ludwig S, Sharma P, Theodoraki M.N, Pietrowska M, Yerneni S.S, Lang S, et al. Molecular and functional profiles of exosomes from HPV(+) and HPV(\u2212) head and neck cancer cell lines. Front Oncol (2018). https:\/\/doi.org\/10.3389\/fonc.2018.00445.","DOI":"10.3389\/fonc.2018.00445"},{"key":"3606_CR11","doi-asserted-by":"publisher","unstructured":"Tengler L, Tiedtke M, Schutz J, Bieback K, Uhlig S, Theodoraki MN, et al. Optimization of extracellular vesicles preparation from saliva of head and neck cancer patients. Sci Rep. 2024. https:\/\/doi.org\/10.1038\/s41598-023-50610-6.","DOI":"10.1038\/s41598-023-50610-6"},{"key":"3606_CR12","doi-asserted-by":"publisher","unstructured":"Beccard IJ, Hofmann L, Schroeder JC, Ludwig S, Laban S, Brunner C, et al. Immune suppressive effects of plasma-derived exosome populations in head and neck cancer. Cancers. 2020. https:\/\/doi.org\/10.3390\/cancers12071997.","DOI":"10.3390\/cancers12071997"},{"key":"3606_CR13","doi-asserted-by":"publisher","unstructured":"Tengler L, Schutz J, Tiedtke M, Jablonska J, Theodoraki MN, Nitschke K, et al. Plasma-derived small extracellular vesicles unleash the angiogenic potential in head and neck cancer patients. Mol Med. 2023. https:\/\/doi.org\/10.1186\/s10020-023-00659-w.","DOI":"10.1186\/s10020-023-00659-w"},{"key":"3606_CR14","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/cei.12354","volume":"177","author":"PJ Schuler","year":"2014","unstructured":"Schuler PJ, Saze Z, Hong CS, Muller L, Gillespie DG, Cheng D, et al. Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells. Clin Exp Immunol. 2014;177:531\u201343.","journal-title":"Clin Exp Immunol"},{"key":"3606_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/bs.acc.2015.12.005","volume":"74","author":"TL Whiteside","year":"2016","unstructured":"Whiteside TL. Tumor-derived exosomes and their role in cancer progression. Adv Clin Chem. 2016;74:103\u201341.","journal-title":"Adv Clin Chem"},{"key":"3606_CR16","doi-asserted-by":"publisher","unstructured":"Affolter A, Liebel K, Tengler L, Seiz E, Tiedtke M, Azhakesan A, et al. Modulation of PD\u2011L1 expression by standard therapy in head and neck cancer cell lines and exosomes. Int J Oncol. 2023. https:\/\/doi.org\/10.3892\/ijo.2023.5550.","DOI":"10.3892\/ijo.2023.5550"},{"key":"3606_CR17","doi-asserted-by":"publisher","unstructured":"Muller L, Simms P, Hong CS, Nishimura MI, Jackson EK, Watkins SC, et al. Human tumor-derived exosomes (TEX) regulate Treg functions via cell surface signaling rather than uptake mechanisms. Oncoimmunology. 2017. https:\/\/doi.org\/10.1080\/2162402X.2016.1261243.","DOI":"10.1080\/2162402X.2016.1261243"},{"key":"3606_CR18","doi-asserted-by":"publisher","unstructured":"Hong CS, Funk S, Muller L, Boyiadzis M, Whiteside TL. Isolation of biologically active and morphologically intact exosomes from plasma of patients with cancer. J Extracell Vesicles. 2016. https:\/\/doi.org\/10.3402\/jev.v5.29289.","DOI":"10.3402\/jev.v5.29289"},{"key":"3606_CR19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11302-020-09699-x","volume":"16","author":"EK Jackson","year":"2020","unstructured":"Jackson EK, Gillespie DG, Cheng D, Mi Z, Menshikova EV. Characterization of the N(6)-etheno-bridge method to assess extracellular metabolism of adenine nucleotides: detection of a possible role for purine nucleoside phosphorylase in adenosine metabolism. Purinergic Signal. 2020;16:187\u2013211.","journal-title":"Purinergic Signal"},{"key":"3606_CR20","doi-asserted-by":"publisher","first-page":"5245","DOI":"10.1158\/0008-5472.CAN-04-0496","volume":"64","author":"CL Andersen","year":"2004","unstructured":"Andersen CL, Jensen JL, Orntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 2004;64:5245\u201350.","journal-title":"Cancer Res"},{"key":"3606_CR21","doi-asserted-by":"publisher","unstructured":"Welsh JA, Goberdhan DCI, O\u2019Driscoll L, Buzas EI, Blenkiron C, Bussolati B, et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles. 2024. https:\/\/doi.org\/10.1002\/jev2.12404.","DOI":"10.1002\/jev2.12404"},{"key":"3606_CR22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/cei.13157","volume":"194","author":"MN Theodoraki","year":"2018","unstructured":"Theodoraki MN, Hoffmann TK, Jackson EK, Whiteside TL. Exosomes in HNSCC plasma as surrogate markers of tumour progression and immune competence. Clin Exp Immunol. 2018;194:67\u201378.","journal-title":"Clin Exp Immunol"},{"key":"3606_CR23","doi-asserted-by":"publisher","unstructured":"Muller L, Mitsuhashi M, Simms P, Gooding WE, Whiteside TL. Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets. Sci Rep. 2016. https:\/\/doi.org\/10.1038\/srep20254.","DOI":"10.1038\/srep20254"},{"key":"3606_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ni.1674","volume":"10","author":"X Yu","year":"2009","unstructured":"Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10:48\u201357.","journal-title":"Nat Immunol"},{"key":"3606_CR25","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1158\/0008-5472.CAN-14-2788","volume":"75","author":"HB Jie","year":"2015","unstructured":"Jie HB, Schuler PJ, Lee SC, Srivastava RM, Argiris A, Ferrone S, et al. CTLA-4(+) regulatory T cells increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis. Cancer Res. 2015;75:2200\u201310.","journal-title":"Cancer Res"},{"key":"3606_CR26","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1006\/smim.1998.0157","volume":"10","author":"DS Vinay","year":"1998","unstructured":"Vinay DS, Kwon BS. Role of 4-1BB in immune responses. Semin Immunol. 1998;10:481\u20139.","journal-title":"Semin Immunol"},{"key":"3606_CR27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ymthe.2024.12.010","volume":"33","author":"KY Lee","year":"2025","unstructured":"Lee KY, Mei Y, Liu H, Schwarz H. CD137-expressing regulatory T cells in cancer and autoimmune diseases. Mol Ther. 2025;33:51\u201370.","journal-title":"Mol Ther"},{"key":"3606_CR28","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/cei.13113","volume":"192","author":"MN Theodoraki","year":"2018","unstructured":"Theodoraki MN, Hoffmann TK, Whiteside TL. Separation of plasma-derived exosomes into CD3(+) and CD3(-) fractions allows for association of immune cell and tumour cell markers with disease activity in HNSCC patients. Clin Exp Immunol. 2018;192:271\u201383.","journal-title":"Clin Exp Immunol"},{"key":"3606_CR29","doi-asserted-by":"publisher","unstructured":"Mejia-Guarnizo LV, Monroy-Camacho PS, Turizo-Smith AD, Rodriguez-Garcia JA. The role of immune checkpoints in antitumor response: a potential antitumor immunotherapy. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1298571.","DOI":"10.3389\/fimmu.2023.1298571"},{"key":"3606_CR30","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/j.1365-2567.2010.03255.x","volume":"129","author":"JS Yi","year":"2010","unstructured":"Yi JS, Cox MA, Zajac AJ. T-cell exhaustion: characteristics, causes and conversion. Immunology. 2010;129:474\u201381.","journal-title":"Immunology"},{"key":"3606_CR31","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nri2489","volume":"9","author":"A Collins","year":"2009","unstructured":"Collins A, Littman DR, Taniuchi I. RUNX proteins in transcription factor networks that regulate T-cell lineage choice. Nat Rev Immunol. 2009;9:106\u201315.","journal-title":"Nat Rev Immunol"},{"key":"3606_CR32","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1146\/annurev-immunol-032712-095946","volume":"31","author":"K Okkenhaug","year":"2013","unstructured":"Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune cells. Annu Rev Immunol. 2013;31:675\u2013704.","journal-title":"Annu Rev Immunol"},{"key":"3606_CR33","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/cyto.a.24334","volume":"99","author":"F Junker","year":"2021","unstructured":"Junker F, Gulati P, Wessels U, Seeber S, Stubenrauch KG, Codarri-Deak L, et al. A human receptor occupancy assay to measure anti-PD-1 binding in patients with prior anti-PD-1. Cytometry A. 2021;99:832\u201343.","journal-title":"Cytometry A"},{"key":"3606_CR34","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cell.2019.02.016","volume":"177","author":"M Poggio","year":"2019","unstructured":"Poggio M, Hu T, Pai CC, Chu B, Belair CD, Chang A, et al. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 2019;177:414\u201327.","journal-title":"Cell"},{"key":"3606_CR35","doi-asserted-by":"publisher","unstructured":"Yin Z, Yu M, Ma T, Zhang C, Huang S, Karimzadeh MR, et al. Mechanisms underlying low-clinical responses to PD-1\/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2020-001698.","DOI":"10.1136\/jitc-2020-001698"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03606-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03606-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03606-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:02:39Z","timestamp":1790456559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03606-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,26]]},"references-count":35,"alternative-id":["3606"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03606-8","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,26]]},"assertion":[{"value":"21 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Written informed consent was obtained from all participants before study inclusion. The local ethics committee, Ethics Committee II, Medical Faculty Mannheim, Heidelberg University, approved the study (2021-552 and 2019-697\u2009N). The study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Consent for publication was obtained from all patients, and patient anonymity was maintained.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Ethics"}}]}}